keyword
MENU ▼
Read by QxMD icon Read
search

Oral vinorelbine

keyword
https://www.readbyqxmd.com/read/27915005/development-and-characterisation-of-disulfiram-loaded-plga-nanoparticles-for-the-treatment-of-non-small-cell-lung-cancer
#1
Mohammad Najlah, Zahima Ahmed, Mohammed Iqbal, Zhipeng Wang, Patrica Tawari, Weiguang Wang, Christopher McConville
Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer in both men and women. A recent phase IIb study demonstrated that disulfiram (DSF) in combination with cisplatin and vinorelbine was well tolerated and prolonged the survival of patients with newly diagnosed NSCLC. However, DSF is rapidly (4 minutes) metabolised in the bloodstream and it is this issue which is limiting its anticancer application in the clinic. We have recently demonstrated that a low dose of DSF-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles supplemented with oral Cu inhibited tumour growth and reduced metastasis in a xenograft mouse lung cancer model...
November 30, 2016: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/27764781/a-phase-ii-open-label-multicenter-study-of-gefitinib-in-combination-with-irradiation-followed-by-chemotherapy-in-patients-with-inoperable-stage-iii-non-small-cell-lung-cancer
#2
Antonin Levy, Etienne Bardet, Benjamin Lacas, Jean-Pierre Pignon, Julien Adam, Ludovic Lacroix, Xavier Artignan, Pierre Verrelle, Cécile Le Péchoux
BACKGROUND: Gefitinib is an oral EGFR tyrosine kinase inhibitors which may act as a radiosensitizer. PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status...
October 18, 2016: Oncotarget
https://www.readbyqxmd.com/read/27760935/-a-multivariate-analysis-of-the-efficacy-of-adjuvant-chemotherapy-in-triple-negative-breast-cancer
#3
Yoshinori Nio, Shiro Imai, Kayo Uesugi, Mikako Tamaoki, Masashi Tamaoki, Riruke Maruyama
Triple-negative breast cancers(TNBCs)are associated with early recurrence after surgery and unfavorable prognoses. To date, no effective therapies for TNBCs have been established. The present study was designed to evaluate the efficacy of adjuvant chemotherapy(ACT)for 111 TNBCs using a retrospective multivariate analysis(MVA). The intravenous(iv)ACTs included docetaxel, epirubicin, gemcitabine, and vinorelbine. The oral ACTs included UFT, doxifluridine, and cyclophosphamide. The 10-year disease-free survival(DFS)and overall survival(OS)rates were 77...
October 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27756583/final-results-of-the-randomized-phase-ii-norcap-ca223-trial-comparing-first-line-all-oral-versus-taxane-based-chemotherapy-for%C3%A2-her2-negative-metastatic-breast-cancer
#4
Saverio Cinieri, Arlene Chan, Kadri Altundag, An Vandebroek, Nicole Tubiana-Mathieu, Agusti Barnadas, Patricia Dodyk, Silvia Lazzarelli, Michiel Botha, Daniel Rauch, Gustavo Villanova, Ugur Coskun
BACKGROUND: The purpose of this study was to evaluate the efficacy of 3 first-line chemotherapy combination regimens for HER2-negative metastatic breast cancer (mBC). PATIENTS AND METHODS: In this open-label, 3-arm, randomized phase II trial, patients were randomized to all-oral NORCAP (vinorelbine/capecitabine), GEMPAC (gemcitabine/paclitaxel), or GEMDOC (gemcitabine/docetaxel) as first-line chemotherapy for HER2-negative mBC. Stratification factors were center, previous (neo)adjuvant anthracycline, and age...
June 25, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27752847/metronomic-chemotherapy-with-oral-vinorelbine-mvnr-and-capecitabine-mcape-in-advanced-her2-negative-breast-cancer-patients-is-it-a-way-to-optimize-disease-control-final-results-of-the-victor-2-study
#5
M E Cazzaniga, L Cortesi, A Ferzi, L Scaltriti, F Cicchiello, M Ciccarese, S Della Torre, F Villa, M Giordano, C Verusio, M Nicolini, A R Gambaro, L Zanlorenzi, E Biraghi, L Legramandi, E Rulli
PURPOSE: The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients. The VICTOR-2 study was designed to confirm these results. METHODS: Patients received mVNR 40 mg three times a week and mCAPE 500 mg three times a day, continuously. The primary endpoint was the clinical benefit rate (CBR); secondary endpoints were toxicity, objective response rate (ORR), and progression-free survival (PFS)...
December 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27647223/efficacy-and-safety-of-vinorelbine-capecitabine-oral-metronomic-combination-in-elderly-metastatic-breast-cancer-patients-victor-1-study
#6
Marina E Cazzaniga, Valter Torri, Francesca Riva, Luca Porcu, Federica Cicchiello, Serena Capici, Diego Cortinovis, Nunzio Digiacomo, Paolo Bidoli
PURPOSE: Elderly patients with metastatic breast cancer are expected to derive similar benefits from chemotherapy as younger patients, but are more likely to experience therapy-related toxicity. Data from the VICTOR-1 study showed that metronomic therapy with vinorelbine and capecitabine was effective and well tolerated in patients with metastatic breast cancer. This analysis determined the efficacy and safety of the metronomic combination of oral vinorelbine and capecitabine in a subgroup of VICTOR-1 study patients aged ≥70 years...
August 24, 2016: Tumori
https://www.readbyqxmd.com/read/27579253/sorafenib-in-breast-cancer-treatment-a-systematic-review-and-overview-of-clinical-trials
#7
Menelaos Zafrakas, Panayiota Papasozomenou, Christos Emmanouilides
AIM: To evaluate the current role of sorafenib, an oral multikinase inhibitor in the treatment of breast cancer. METHODS: An extensive search of the literature until March 2016 was carried out in Medline and clinicaltrials.gov, by using the search terms "sorafenib" and "breast cancer". Papers found were checked for further relevant publications. Overall, 21 relevant studies were found, 18 in advanced breast cancer (16 in stage IV and two in stages III-IV) and three in early breast cancer...
August 10, 2016: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27557783/clinical-pharmacodynamic-and-pharmacokinetic-results-of-a-prospective-phase-ii-study-on-oral-metronomic-vinorelbine-and-dexamethasone-in-castration-resistant-prostate-cancer-patients
#8
Teresa Di Desidero, Lisa Derosa, Luca Galli, Paola Orlandi, Andrea Fontana, Anna Fioravanti, Riccardo Marconcini, Mario Giorgi, Beatrice Campi, Alessandro Saba, Sara Lucchesi, Renato Felipetto, Romano Danesi, Giulio Francia, Giacomo Allegrini, Alfredo Falcone, Guido Bocci
The aim of the present study was to evaluate clinical activity, and the pharmacodynamic and pharmacokinetic profiles, of oral metronomic vinorelbine (VNR) plus dexamethasone (DEX) in metastatic castration-resistant prostate cancer (mCRPC) patients. Fourty-one patients (92 % chemotherapy-resistant) received 30 mg/day VNR p.o. thrice a week plus 1 mg/day DEX p.o. until disease progression. Plasma soluble B cell antigen 7 homolog 3 (sB7-H3), vascular endothelial growth factor (VEGF), and thrombospondin-1 (TSP-1), were measured by ELISA...
December 2016: Investigational New Drugs
https://www.readbyqxmd.com/read/27388853/burden-of-advanced-breast-cancer-for-patients-and-caregivers-in-europe-comparison-of-two-treatment-forms-of-vinorelbine-oral-and-intravenous
#9
Sandro Barni, Beata Freier, Isabel Garau, Jean-Loup Mouysset, Marcela Sediva, Claudio Zamagni, Gilles Berdeaux, Cecilia de Almeida Agudo
AIM: To assess the burden of disease associated with advanced breast cancer (ABC) treated with oral (VinO) or intravenous vinorelbine (VinIV) from the perspective of patients and caregivers in five European countries. METHODS: This was an observational, prospective, international, multicenter study. Patients were included in the study at the beginning of their second cycle of chemotherapy with vinorelbine and categorized into two groups depending on whether they received VinO or VinIV...
November 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27330293/preparation-characterization-and-evaluation-of-antitumor-effect-of-brucea-javanica-oil-cationic-nanoemulsions
#10
Ting-Ting Liu, Li-Qiu Mu, Wei Dai, Chuan-Bang Wang, Xin-Yi Liu, Da-Xiong Xiang
The purpose of this study was to prepare Brucea javanica oil cationic nanoemulsions (BJO-CN) with BJO as drug as well as oil phase and chitosan as cationic inducer, to explore the practical suitability of using cationic nanoemulsions for oral delivery of mixed oil, and to test its bioavailability and antitumor effect. BJO-CN was prepared by chitosan solution stirring method and then characterized physicochemically. The obtained BJO-CN had a spherical morphology with a positive zeta potential of 18.9 mV and an average particle size of 42...
2016: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/27223813/oral-vinorelbine-plus-cisplatin-versus-pemetrexed-plus-cisplatin-as-first-line-treatment-of-advanced-non-squamous-non-small-cell-lung-cancer-cost-minimization-analysis-in-12-european-countries
#11
Francesco Grossi, Jaafar Bennouna, Libor Havel, Maximillian Hochmair, Teresa Almodovar
OBJECTIVE: A combination of vinorelbine and cisplatin is a standard treatment in non-small-cell lung cancer; oral vinorelbine is registered in 45 countries. Pemetrexed and cisplatin are recommended in front-line chemotherapy of non-squamous non-small-cell lung cancer (NS-NSCLC). The objective of this study was to conduct a cost minimization analysis from the perspective of the national health service (NHS) in each of 12 European countries, based on a randomized phase II study in NS-NSCLC (NAVoTRIAL01), with 100 oral vinorelbine plus cisplatin patients (arm A) and 51 pemetrexed plus cisplatin patients (arm B)...
September 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27164855/chemotherapy-principles-of-managing-stage-iv-breast-cancer-in-the-united-states
#12
Leonel F Hernandez-Aya, Cynthia X Ma
The therapeutic landscape for metastatic breast cancer (MBC) has expanded greatly over the last three decades with an increasing availability of targeted therapies for specific breast cancer subtypes. However, cytotoxic chemotherapy remains an essential component for the management of endocrine refractory or triple negative MBC. Multiple chemotherapy agents have demonstrated activity in MBC as single agents and in combination. While taxanes are frequently recommended as the initial treatment of metastatic disease, capecitabine is a convenient oral therapy with well received toxicity profile...
June 2016: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/27143931/oral-vinorelbine-a-feasible-and-safe-partner-for-radiotherapy-in-the-treatment-of-locally-advanced-non-small-cell-lung-cancer
#13
REVIEW
Francesco Perri, Grazia Lazzari, Giuseppina Della Vittoria Scarpati, Giovanni Silvano
BACKGROUND: Concurrent chemoradiotherapy (CCRT) using cisplatin-based doublets represents the standard of care for locally advanced non-small cell lung cancer (NSCLC), having shown good efficacy and activity in clinical trials. Locally advanced NSCLC occurs frequently in the elderly population, which is often excluded by platinum-based CCRT administration, due to severe associated toxicities. This limitation has been overcome using new-generation drugs such as gemcitabine, docetaxel, paclitaxel, and vinorelbine, which have shown not only to be efficacious but also to have a favorable toxicity spectrum, both in association with cisplatin and as single agents...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27135612/phase-i-study-of-oral-vinorelbine-in-combination-with-erlotinib-in-advanced-non-small-cell-lung-cancer-nsclc-using-two-different-schedules
#14
Natalia Sutiman, Zhenxian Zhang, Eng Huat Tan, Mei Kim Ang, Shao-Weng Daniel Tan, Chee Keong Toh, Quan Sing Ng, Balram Chowbay, Wan-Teck Lim
PURPOSE: This study aimed to evaluate the safety, tolerability and pharmacokinetics of the combination of oral vinorelbine with erlotinib using the conventional (CSV) and metronomic (MSV) dosing schedules in patients with advanced non-small cell lung cancer (NSCLC). METHODS: This was an open-label, multiple dose-escalation phase I study. An alternating 3+3 phase I design was employed to allow each schedule to enroll three patients sequentially at each dose level...
2016: PloS One
https://www.readbyqxmd.com/read/27094927/a-phase-ia-ib-clinical-trial-of-metronomic-chemotherapy-based-on-a-mathematical-model-of-oral-vinorelbine-in-metastatic-non-small-cell-lung-cancer-and-malignant-pleural-mesothelioma-rationale-and-study-protocol
#15
Xavier Elharrar, Dominique Barbolosi, Joseph Ciccolini, Christophe Meille, Christian Faivre, Bruno Lacarelle, Nicolas André, Fabrice Barlesi
BACKGROUND: Metronomic oral vinorelbine is effective in metastatic NSCLC and malignant pleural mesothelioma, but all the studies published thus far were based upon a variety of empirical and possibly suboptimal schedules, with inconsistent results. Mathematical modelling showed by simulation that a new metronomic protocol could lead to a better safety and efficacy profile. DESIGN: This phase Ia/Ib trial was designed to confirm safety (phase Ia) and evaluate efficacy (phase Ib) of a new metronomic oral vinorelbine schedule...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27059339/oral-vinorelbine-in-combination-with-trastuzumab-as-a-first-line-therapy-of-metastatic-or-locally-advanced-her2-positive-breast-cancer
#16
Fadi Farhat, Joseph G Kattan, Marwan Ghosn
PURPOSE: Vinorelbine-trastuzumab combination proved to be an effective first-line treatment for patients with locally advanced or metastatic breast cancer (MBC). Oral chemotherapy represents a step forward in MBC management. To improve patients' comfort using the oral form of vinorelbine, we conducted a multicenter phase II study to investigate the efficacy and safety of the oral vinorelbine-trastuzumab combination in women with MBC with human epidermal growth factor receptor 2 (HER2) overexpression...
May 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27051392/dose-dense-chemotherapy-in-metastatic-breast-cancer-shortening-the-time-interval-for-a-better-therapeutic-index
#17
REVIEW
Marcus Schmidt
Despite the advancement of targeted therapies in metastatic breast cancer, chemotherapy is still of pivotal importance. The concept of dose density is known to increase the efficacy of chemotherapy. In metastatic disease, preservation of the quality of life is equally important. Because of this, weekly regimens are a cornerstone in metastatic disease. Taxanes like paclitaxel or nab-paclitaxel as well as antracyclines are often used in palliative treatment. Further advances to increase dose density have led to the concept of daily metronomic schedules with oral chemotherapeutic drugs like cyclophosphamide, capecitabine, or vinorelbine...
February 2016: Breast Care
https://www.readbyqxmd.com/read/27014659/chemotherapy-in-frail-elderly-patients-with-hormone-refractory-prostate-cancer-a-real-world-experience
#18
Paolo Tralongo, Sebastiano Bordonaro, Annamaria Di Mari, Francesco Cappuccio, Sebastiano Rametta Giuliano
BACKGROUND: In elderly patients affected by metastatic castration-resistant prostate cancer (mCRPC) chemotherapic treatment may be the choice if one considers not only the chronological age, but also the clinical status, the functional reserve, and the vulnerability of patients. Several studies have confirmed the survival benefit of docetaxel and vinorelbine among every class of age. Most CRP elderly patients are defined as frail, maybe due to comorbidities: these patients, who are unable to be candidates for a standard treatment, should be candidates for a more tolerable treatment...
March 2016: Prostate International
https://www.readbyqxmd.com/read/26927446/capecitabine-and-bevacizumab-with-or-without-vinorelbine-in-first-line-treatment-of-her2-neu-negative-metastatic-or-locally-advanced-breast-cancer-final-efficacy-and-safety-data-of-the-randomised-open-label-superiority-phase-3-carin-trial
#19
A Welt, N Marschner, C Lerchenmueller, T Decker, C-C Steffens, A Koehler, R Depenbusch, S Busies, S Hegewisch-Becker
The study was designed to evaluate efficacy and superiority of capecitabine/bevacizumab + vinorelbine (CAP/BEV/VIN) compared to CAP/BEV alone. Main purpose was to introduce a taxane-/anthracycline-free first-line treatment in advanced breast cancer (ABC), in order to avoid long-term toxicities. In this open-label, superiority, phase 3 trial, patients with HER2-negative ABC were randomized 1:1 to receive either oral CAP at 1000 mg/m(2) [twice daily, days 1-14, q3w] plus intravenous BEV at 15 mg/kg [day 1, q3w] (arm A) or in addition to this protocol intravenous VIN at 25 mg/m(2) [days 1 + 8, q3w] (arm B) until disease progression, unacceptable toxicity or withdrawal of consent...
February 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/26822398/afatinib-plus-vinorelbine-versus-trastuzumab-plus-vinorelbine-in-patients-with-her2-overexpressing-metastatic-breast-cancer-who-had-progressed-on-one-previous-trastuzumab-treatment-lux-breast-1-an-open-label-randomised-phase-3-trial
#20
RANDOMIZED CONTROLLED TRIAL
Nadia Harbeck, Chiun-Sheng Huang, Sara Hurvitz, Dah-Cherng Yeh, Zhimin Shao, Seock-Ah Im, Kyung Hae Jung, Kunwei Shen, Jungsil Ro, Jacek Jassem, Qingyuan Zhang, Young-Hyuck Im, Marek Wojtukiewicz, Qiang Sun, Shin-Cheh Chen, Rainer-Georg Goeldner, Martina Uttenreuther-Fischer, Binghe Xu, Martine Piccart-Gebhart
BACKGROUND: Trastuzumab resistance is a key therapeutic challenge in metastatic breast cancer. We postulated that broader inhibition of ErbB receptors with afatinib would improve clinical outcomes compared with HER2 inhibition alone in patients who had progressed on previous trastuzumab treatment. LUX-Breast 1 compared afatinib plus vinorelbine with trastuzumab plus vinorelbine for such patients with HER2-positive metastatic breast cancer. METHODS: We did this open-label trial at 350 hospitals in 41 countries worldwide...
March 2016: Lancet Oncology
keyword
keyword
31936
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"